N/A N=73 The Effects of Dexamethasone on the Time to Pain Resolution in Dental Periapical Abscess
Dental Research · Pharmaceutical Preparations, Dental
Primary: Decrease Time of Oral Pain — 9; 9; 5; 4 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=91 Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Per RECIST 1.1 — 0.395; 0.404 proportion of participants — p=0.2176
Phase 3 N=402 Randomized Trial of Adult Participants With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in the HAM-A Total Score at Week 8 — -9.28; -9.35 score on a scale — p=0.917
Phase 2 N=30 Mesenchymal Stemcells for Radiation Induced Xerostomia
Xerostomia
Primary: Number of Participants With Adverse Events as a Measure of Safety — 0; 0 participants
Phase 4 N=384 Safety of RIV4 Versus IIV4 in Pregnant Women
Safety · Adverse Event Following Immunisation · Birth Outcomes
Primary: Number of Pregnant Women Vaccinated With RIV4 Versus IIV4 With Adverse Birth Outcomes — 17; 21 Participants — p=<0.0001
Phase 3 N=352 A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
Molluscum Contagiosum
Primary: Complete Clearance of All Treatable MC at Week 12 — 61; 25 Participants
N/A N=704 Optimizing Viral Load Suppression in Kenyan Children on Antiretroviral Therapy
Chronic HIV Infection
Primary: Number of Participants With Viral Suppression — 289; 283 participants — p=0.55
Phase 2 N=24 A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
Pancreatic Cancer · Pancreas Adenocarcinoma · Advanced Pancreatic Cancer
Primary: Progression- Free Survival at 6 Months From Initiation of Trial Treatment — 0; 2 Participants — p=.31
Phase 2 N=38 Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Graft Versus Host Disease · Leukemia · Myelodysplastic Syndromes
Primary: Response to Therapy — 1; 0; 27; 4 Participants
Phase 4 N=336 Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue
Multiple Sclerosis
Primary: Change in the Modified Fatigue Impact Scale (MFIS) Score — -15.2; -16.0; -17.3 score on a scale — p=0.3451
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
N/A N=720 Building on Needle Exchange to Optimize Prevention & Treatment
Intravenous Drug Usage · HIV/AIDS
Primary: Composite PWID Score (Service Access, Risk Behaviors, Adverse Outcomes) — 5.34; 5.64 units on a scale — p=0.125
N/A N=48 Imaging Biomarkers of Knee Osteoarthritis
Osteoarthritis
Primary: Change From Baseline in T1ρ Relaxation Time — 2.1; 13.3 milliseconds
Phase 2 N=11 Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Leber's Congenital Amaurosis
Primary: Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes — 6; 5 Participants
N/A N=32 Clinician Communication About Sexual Health
Breast Cancer
Primary: Feasibility of the Intervention Trial - Enrollment — 96.97 percent of eligible study candidates